No Yes Ok

Archive

« Older Entries

Sanofi Submits New Drug Application for the Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Wednesday, December 23rd, 2015
Paris, France - December 23, 2015 - Sanofi announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational fixed-ratio combination of insulin g [...]
Nexstim announces the result of its private placement Thursday, December 17th, 2015
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, CANADA, HONG KONG, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTIO [...]
Xeltis extends series B financing to €30M, signing off transformational year Thursday, December 17th, 2015
In 2015: positive results from first two clinical trials, stronger leadership team and corporate recognitions   Zurich, Switzerland, 17 December 2015 – Xeltis has completed a €3 million extension to its s [...]
Merus Appoints Hui Liu as Chief Business Officer Wednesday, December 16th, 2015
Novartis Oncology’s Former Global Head of Business Development and Licensing Joins Immuno-oncology Biotech Company   UTRECHT, The Netherlands, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stag [...]
Probiodrug announces publication of initial PQ912 clinical data demonstrating inhibition of glutaminyl cyclase Tuesday, December 15th, 2015
PQ912 is currently in Phase 2a studies in Alzheimer’s disease patients   HALLE/SAALE, Germany, 15 December 2015 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel ther [...]
Hybrigenics receives green light for a double-blind placebo-controlled Phase II clinical study of inecalcitol in Acute Myeloid Leukemia (AML) Monday, December 14th, 2015
Hybrigenics has received the authorization by the French Drug Agency to perform a clinical Phase II study of inecalcitol in older or frail AML patients Hybrigenics has filed an application to the American Fo [...]
Affimed Added to NASDAQ Biotech Index® Monday, December 14th, 2015
Heidelberg, Germany, December 14, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that the C [...]
LSP V company Kuros to combine with Cytos Thursday, December 3rd, 2015
Cytos Biotechnology and Kuros Biosurgery to combine to create Kuros Biosciences   Combined company aims to be a leader in the field of tissue repair and regeneration Late-stage clinical pipeline of no [...]
Nexstim Plc Announces Completion of Enrolment of Phase III Clinical Trial in Stroke Therapy Thursday, December 3rd, 2015
- Recruitment completed ahead of schedule   Helsinki, 3 December 2015, Nexstim Plc (NXTMH:HEX, NXTMS:STO) a medical technology company aiming to improve rehabilitation for stroke patients through the use of n [...]
LSP and Bristol-Myers Squibb enter into strategic collaboration for life sciences innovation in Europe Tuesday, November 24th, 2015
First investment by Bristol-Myers Squibb in a European healthcare fund      Munich and New York, 24 November, 2015—LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced to [...]

« Older Entries

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries

Sanofi Submits New Drug Application for the Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Wednesday, December 23rd, 2015
Paris, France - December 23, 2015 - Sanofi announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational fixed-ratio combination of insulin g [...]
Nexstim announces the result of its private placement Thursday, December 17th, 2015
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, CANADA, HONG KONG, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTIO [...]
Xeltis extends series B financing to €30M, signing off transformational year Thursday, December 17th, 2015
In 2015: positive results from first two clinical trials, stronger leadership team and corporate recognitions   Zurich, Switzerland, 17 December 2015 – Xeltis has completed a €3 million extension to its s [...]
Merus Appoints Hui Liu as Chief Business Officer Wednesday, December 16th, 2015
Novartis Oncology’s Former Global Head of Business Development and Licensing Joins Immuno-oncology Biotech Company   UTRECHT, The Netherlands, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stag [...]
Probiodrug announces publication of initial PQ912 clinical data demonstrating inhibition of glutaminyl cyclase Tuesday, December 15th, 2015
PQ912 is currently in Phase 2a studies in Alzheimer’s disease patients   HALLE/SAALE, Germany, 15 December 2015 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel ther [...]
Hybrigenics receives green light for a double-blind placebo-controlled Phase II clinical study of inecalcitol in Acute Myeloid Leukemia (AML) Monday, December 14th, 2015
Hybrigenics has received the authorization by the French Drug Agency to perform a clinical Phase II study of inecalcitol in older or frail AML patients Hybrigenics has filed an application to the American Fo [...]
Affimed Added to NASDAQ Biotech Index® Monday, December 14th, 2015
Heidelberg, Germany, December 14, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that the C [...]
LSP V company Kuros to combine with Cytos Thursday, December 3rd, 2015
Cytos Biotechnology and Kuros Biosurgery to combine to create Kuros Biosciences   Combined company aims to be a leader in the field of tissue repair and regeneration Late-stage clinical pipeline of no [...]
Nexstim Plc Announces Completion of Enrolment of Phase III Clinical Trial in Stroke Therapy Thursday, December 3rd, 2015
- Recruitment completed ahead of schedule   Helsinki, 3 December 2015, Nexstim Plc (NXTMH:HEX, NXTMS:STO) a medical technology company aiming to improve rehabilitation for stroke patients through the use of n [...]
LSP and Bristol-Myers Squibb enter into strategic collaboration for life sciences innovation in Europe Tuesday, November 24th, 2015
First investment by Bristol-Myers Squibb in a European healthcare fund      Munich and New York, 24 November, 2015—LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced to [...]

« Older Entries

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund